Last reviewed · How we verify
EGCG as putative neuroprotective agent
EGCG (epigallocatechin gallate) is a polyphenol from green tea that exerts neuroprotection through antioxidant and anti-inflammatory pathways, reducing neuronal damage and protein aggregation.
EGCG (epigallocatechin gallate) is a polyphenol from green tea that exerts neuroprotection through antioxidant and anti-inflammatory pathways, reducing neuronal damage and protein aggregation. Used for Neuroprotection in neurodegenerative disease (specific indication not publicly detailed).
At a glance
| Generic name | EGCG as putative neuroprotective agent |
|---|---|
| Also known as | Sunphenon EGCg |
| Sponsor | Dr. Johannes Levin |
| Drug class | Natural polyphenol / antioxidant |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
EGCG is a catechin polyphenol that crosses the blood-brain barrier and scavenges reactive oxygen species while inhibiting pro-inflammatory signaling cascades implicated in neurodegeneration. It may also modulate protein misfolding and aggregation pathways relevant to neurodegenerative diseases, potentially stabilizing neuronal function and reducing cell death.
Approved indications
- Neuroprotection in neurodegenerative disease (specific indication not publicly detailed)
Common side effects
- Gastrointestinal upset
- Hepatotoxicity (at high doses)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EGCG as putative neuroprotective agent CI brief — competitive landscape report
- EGCG as putative neuroprotective agent updates RSS · CI watch RSS
- Dr. Johannes Levin portfolio CI